Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00566761

Acronym

MECROV

Enrollment

Registered

2007-12-04

Start date

2007-06-30

Completion date

2008-03-31

Last updated

2024-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Retinal Vein Occlusion, Macular Edema

Keywords

Macular edema, central retinal vein occlusion, bevacizumab, triamcinolone

Brief summary

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Detailed description

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Interventions

DRUGbevacizumab and triamcinolone

three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Macular edema secondary to central retinal vein occlusion * BCVA worse than 20/40 * Central macular \>250 mc with OCT

Exclusion criteria

* Diabetic retinopathy or other retinopathy * Media opacity that does not allow following * steroid responder * diagnosed glaucoma or IOP \> 21 mmHg

Design outcomes

Primary

Measure	Time frame
Changes in Best corrected visual acuity and macular edema measured with OCT	Follow up to 3 , 6 and 12 months

Secondary

Measure	Time frame
Report treatment complications	12 month

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026